Why the study?
Does valsartan improve echocardiographic variables of left ventricular hypertrophy in patients with mild to moderate essential hypertension?
Does valsartan improve echocardiographic variables of left ventricular hypertrophy in patients with mild to moderate essential hypertension?
Valsartan effectively controls blood pressure and favorably influences cardiac structure by reducing left ventricular hypertrophy in patients with mild to moderate hypertension.
Valsartan-associated LVH regression in hypertension should not yet change practice; leaves open need for RCTs to confirm effects.
Recent studies demonstrate that, treatment with angiotensin-converting enzyme (ACE) inhibitors and angiotensin-II receptor blockers may decrease left ventricular hypertrophy (LVH) in hypertensive patients. We wanted to assess the efficacy of valsartan on echocardiographic variables of LVH in 30 mild to moderate hypertensive patients. Valsartan was found effective in controlling hypertension, also echocardiographic indices of LVH such as interventricular septum and posterior wall thickness were reduced and left ventricular mass decreased significantly. Thus valsartan favorably influences cardiac structure in hypertensive patients.
No takes yet. Share an insight, caveat, or question.
Mutlu et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: